Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing –remitting multiple sclerosis in Austria
ConclusionsHorizontal switching after a platform therapy resulted in a higher relapse and interrupt probability and was associated with a trend towards less EDSS improvement comparing to vertical switching in Austrian RRMS patients. (Source: Journal of Neurology)
Source: Journal of Neurology - March 2, 2023 Category: Neurology Source Type: research
A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study
CONCLUSIONS: Based on a large real-world cohort, our results confirm the durable reduction of the ARR described in pivot studies. Switching from moderate-efficacy DMT to fingolimod decreased the relapse risk. Switching patients from high-efficacy DMT increased risk of relapse, but the overall five-years ARR remained stable.PMID:36841644 | DOI:10.1016/j.neurol.2022.11.012 (Source: Revue Neurologique)
Source: Revue Neurologique - February 25, 2023 Category: Neurology Authors: L Gauer K Bigaut É Berger M Debouverie T Moreau J de S èze Source Type: research
SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments
DiscussionA possible explanation for the altered immune response in fingolimod- treated MS individuals could be due to the medication inhibiting the circulation of lymphocytes, and possibly in turn inhibiting antibody production. Overall, patients on DMTs are generally of no disadvantage toward mounting an immune response against the vaccine. Nevertheless, further studies require evaluating non-humoral immunity against SARS-CoV-2 following vaccination, as well as the suitability of such vaccinations on patients treated with fingolimod. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - February 24, 2023 Category: Neurology Source Type: research
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature
ConclusionDTT is a promising approach to improve IBD treatment for patients with incomplete responses to targeted monotherapy. Larger prospective clinical studies are needed to confirm these findings as is additional predictive modeling to identify the patient subgroups most likely to require and benefit from this approach. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - February 20, 2023 Category: Gastroenterology Source Type: research
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
ConclusionsThese results suggest that humoral response to mRNA-1273 COVID-19 vaccine is preserved and similar in PwMS treated with natalizumab, fumarate, and interferon beta, but muted with ocrelizumab. All DMTs had preserved T cell response, including the ocrelizumab cohort, which also had a greater risk of vaccine-related side effects. (Source: Neurology and Therapy)
Source: Neurology and Therapy - February 16, 2023 Category: Neurology Source Type: research
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient ‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
ConclusionThese results further extend our knowledge of the effectiveness, specifically regarding improvements in cognitive processing speed, disability and PROs, of long-term natalizumab treatment in early RRMS patients.Clinicaltrials.govNCT01485003 (5 December 2011) (Source: CNS Drugs)
Source: CNS Drugs - February 13, 2023 Category: Neurology Source Type: research
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
ConclusionThese results support the pertinence of using an EID strategy for RRMS patients treated with natalizumab.Clinical Trialsgov identifier (NCT04580381). (Source: Neurology and Therapy)
Source: Neurology and Therapy - February 10, 2023 Category: Neurology Source Type: research
An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
Cureus. 2023 Jan 2;15(1):e33242. doi: 10.7759/cureus.33242. eCollection 2023 Jan.ABSTRACTMultiple sclerosis (MS) is an immune-inflammatory disease that attacks and damages myelinated axons in the central nervous system (CNS) and causes nontraumatic neurological impairment in young people. Historically, Lidwina of Schiedam documented the first MS case. After that, Augustus d'Este wrote for years about how his MS symptoms worsened. Age, sex, genetics, environment, smoking, injuries, and infections, including herpes simplex and rabies, are risk factors for MS. According to epidemiology, the average age of onset is between 20 ...
Source: Herpes - February 3, 2023 Category: Infectious Diseases Authors: Ibrahim M Dighriri Ahood A Aldalbahi Fatimah Albeladi Asimah A Tahiri Elaf M Kinani Rand A Almohsen Nouf H Alamoudi Abeer A Alanazi Sultan J Alkhamshi Noha A Althomali Sultan N Alrubaiei Faisal K Altowairqi Source Type: research
An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
Cureus. 2023 Jan 2;15(1):e33242. doi: 10.7759/cureus.33242. eCollection 2023 Jan.ABSTRACTMultiple sclerosis (MS) is an immune-inflammatory disease that attacks and damages myelinated axons in the central nervous system (CNS) and causes nontraumatic neurological impairment in young people. Historically, Lidwina of Schiedam documented the first MS case. After that, Augustus d'Este wrote for years about how his MS symptoms worsened. Age, sex, genetics, environment, smoking, injuries, and infections, including herpes simplex and rabies, are risk factors for MS. According to epidemiology, the average age of onset is between 20 ...
Source: Herpes - February 3, 2023 Category: Infectious Diseases Authors: Ibrahim M Dighriri Ahood A Aldalbahi Fatimah Albeladi Asimah A Tahiri Elaf M Kinani Rand A Almohsen Nouf H Alamoudi Abeer A Alanazi Sultan J Alkhamshi Noha A Althomali Sultan N Alrubaiei Faisal K Altowairqi Source Type: research
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
In conclusion, switching from EID-natalizumab to ocrelizumab can be considered as a therapeutic option, particularly in patients with MS at high risk of PML, to mitigate the risks of both PML and disease reactivation. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - February 1, 2023 Category: Allergy & Immunology Source Type: research
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis
This randomized clinical trial evaluates matching efficacy, safety, and immunogenicity between biosimilar natalizumab and reference natalizumab in patients with relapsing-remitting multiple sclerosis. (Source: JAMA Neurology)
Source: JAMA Neurology - January 23, 2023 Category: Neurology Source Type: research
Pediatric Multiple Sclerosis —Experience of a Tertiary Care Center
Conclusion About half of patients in this cohort were on second-line disease-modifying treatment, with 19% showing cognitive impairment. Efforts to establish an early diagnosis are crucial to improving these patients' outcomes. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text (Source: Neuropediatrics)
Source: Neuropediatrics - January 16, 2023 Category: Neurology Authors: Martins, Cec ília Sam ões, Raquel Silva, Ana Martins Santos, Ernestina Figueiroa, S ónia Tags: Original Article Source Type: research
CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
CONCLUSION: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.PMID:36635139 | DOI:10.1016/j.vaccine.2023.01.003 (Source: Vaccine)
Source: Vaccine - January 12, 2023 Category: Allergy & Immunology Authors: Narges Ebrahimi Mahsa Mazdak Vahid Shaygannejad Omid Mirmosayyeb Source Type: research
